China SXT Pharmaceuticals (SXTC) Common Equity (2018 - 2025)

China SXT Pharmaceuticals' Common Equity history runs 8 years deep, the most recent figure standing at $20.2 million for Q3 2025.

• In Q3 2025, Common Equity rose 34.58% year-over-year to $20.2 million; the TTM figure through Sep 2025 stood at $20.2 million (up 34.58% YoY), while the FY2025 annual figure was $15.4 million, up 10.83% from the prior year.
• Common Equity was $20.2 million for Q3 2025 at China SXT Pharmaceuticals, up from $15.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $20.2 million in Q3 2025 to a low of $5.1 million in Q3 2023.
• Historically, Common Equity has averaged $14.5 million across 5 years, with a median of $15.0 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Common Equity tumbled 65.91% in 2023, then jumped 196.18% in 2024.
• A 5-year view of Common Equity shows it stood at $13.8 million in 2021, then advanced by 7.96% to $14.9 million in 2022, then sank by 65.91% to $5.1 million in 2023, then surged by 196.18% to $15.0 million in 2024, then surged by 34.58% to $20.2 million in 2025.
• The last three Common Equity figures came in at $20.2 million (Q3 2025), $15.4 million (Q1 2025), and $15.0 million (Q3 2024), per Business Quant data.